Fruquintinib May Edge Ahead in KRAS-Mutant Colorectal Cancer, But No Clear Winner Yet
A Bayesian network meta-analysis of ten randomized trials finds that fruquintinib, regorafenib, and TAS-102 all extend survival in refractory metastatic ...
A Bayesian network meta-analysis of ten randomized trials finds that fruquintinib, regorafenib, and TAS-102 all extend survival in refractory metastatic ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine